Purine metabolism controls innate lymphoid cell function and protects against intestinal injury
Open Access
- 10 July 2018
- journal article
- research article
- Published by Wiley in Immunology & Cell Biology
- Vol. 96 (10) , 1049-1059
Abstract
Inflammatory bowel disease (IBD) is a condition of chronic inflammatory intestinal disorder with increasing prevalence but limited effective therapies. The purine metabolic pathway is involved in various inflammatory processes including IBD. However, the mechanisms through which purine metabolism modulates IBD remain to be established. Here, we found that mucosal expression of genes involved in the purine metabolic pathway is altered in patients with active ulcerative colitis (UC), which is associated with elevated gene expression signatures of the group 3 innate lymphoid cell (ILC3)–interleukin (IL)‐22 pathway. In mice, blockade of ectonucleotidases (NTPDases), critical enzymes for purine metabolism by hydrolysis of extracellular adenosine 5′‐triphosphate (eATP) into adenosine, exacerbates dextran‐sulfate sodium‐induced intestinal injury. This exacerbation of colitis is associated with reduction of colonic IL‐22‐producing ILC3s, which afford essential protection against intestinal inflammation, and is rescued by exogenous IL‐22. Mechanistically, activation of ILC3s for IL‐22 production is reciprocally mediated by eATP and adenosine. These findings reveal that the NTPDase‐mediated balance between eATP and adenosine regulates ILC3 cell function to provide protection against intestinal injury and suggest potential therapeutic strategies for treating IBD by targeting the purine–ILC3 axis.Keywords
Funding Information
- Wellcome Trust
- Medical Research Council (MR/R008167/1, MR/K013386/1)
- Cancer Research UK (C63480, A25246)
- Biotechnology and Biological Sciences Research Council (BB/K091121/1)
- University of Edinburgh
This publication has 52 references indexed in Scilit:
- Purinergic Signaling during InflammationNew England Journal of Medicine, 2012
- Activation of neuronal P2X7 receptor–pannexin-1 mediates death of enteric neurons during colitisNature Medicine, 2012
- Extracellular ATP mediates mast cell-dependent intestinal inflammation through P2X7 purinoceptorsNature Communications, 2012
- IL-23–responsive innate lymphoid cells are increased in inflammatory bowel diseaseJournal of Experimental Medicine, 2011
- CD39 deletion exacerbates experimental murine colitis and human polymorphisms increase susceptibility to inflammatory bowel diseaseProceedings of the National Academy of Sciences, 2009
- STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healingJournal of Experimental Medicine, 2009
- Innate and Adaptive Interleukin-22 Protects Mice from Inflammatory Bowel DiseaseImmunity, 2008
- Blockade of adenosine A2B receptors ameliorates murine colitisBritish Journal of Pharmacology, 2008
- IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitisJournal of Clinical Investigation, 2008
- Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppressionJournal of Experimental Medicine, 2007